Business Description
Founded in 2015 and headquartered in Glenhaven, Australia, Noxopharm is a biotechnology company focused on developing new treatments for cancer, inflammatory conditions, and autoimmune diseases, as well as next-generation mRNA vaccines. The company operates two core research platforms: Sofra, which works on immune-regulating agents to enhance mRNA vaccines and therapies, and Chroma, which is advancing a dual-cell cancer treatment targeting pancreatic cancer alongside therapies for autoimmune and hyperinflammatory conditions. Noxopharm also runs its IONIC program, combining its drug Veyonda with Bristol Myers Squibb's Opdivo to treat multiple solid tumor types, while pursuing orphan drug designations for rarer diseases.
